STCube, Inc. (KOSDAQ:052020)

South Korea flag South Korea · Delayed Price · Currency is KRW
10,500
+730 (7.47%)
Jun 9, 2026, 3:30 PM KST
Market Cap713.30B +88.2%
Revenue (ttm)6.54B -37.7%
Net Income-23.98B
EPS-353.02
Shares Out 67.93M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume437,203
Open10,150
Previous Close9,770
Day's Range9,880 - 10,890
52-Week Range6,400 - 22,500
Beta-0.66
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About STCube

STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods. The company’s product pi... [Read more]

Industry Technology Distributors
Sector Technology
Founded 1989
Employees 13
Stock Exchange KOSDAQ
Ticker Symbol 052020
Full Company Profile

Financial Performance

In 2025, STCube's revenue was 6.98 billion, a decrease of -38.18% compared to the previous year's 11.30 billion. Losses were -21.80 billion, 1.69% more than in 2024.

Financial Statements